等待开盘 05-27 09:30:00 美东时间
-0.110
-1.58%
今日重点评级关注:Oppenheimer:维持Protara Therapeutics"跑赢大市"评级,目标价从25美元升至28美元;Piper Sandler:维持Bright Minds Biosciences"超配"评级,目标价从190美元升至220美元
05-21 12:05
TD Cowen analyst Oliver Chen maintains LuxExperience (NYSE:LUXE) with a Buy and lowers the price target from $12 to $8.
05-21 00:36
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据LuxExperience业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **集团层面:** - 净销售额:按固定汇率计算保持稳定,但受欧元兑美元汇率影响,报告净销售额同比下降5.2% - 调整后EBITDA利润率:第三季度为正0.9%,实现连续第二个季度盈利 - 经营现金流:前九个月为负1.179亿欧元 - 现金及现金等价物:4.361亿欧元,总可用资金6.128亿欧元 **分业务板块:** - Mytheresa净销售额:按固定汇率计算增长9.9%至2.56亿欧元 - NET-A-PORTER和MR PORTER净销售额:按固定汇
05-20 12:31
LuxExperience shares are trading lower after the company reported worse-than-ex...
05-20 02:09
Companies Reporting Before The Bell • Radcom (NASDAQ:RDCM) is expected to repor...
05-19 19:11
LuxExperience (NYSE:LUXE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.18) by 61.11 percent. This is a 583.33 percent decrease over earnings of $0.06 per share from
05-19 18:04
今日重点评级关注:Ascendiant Capital:维持Banzai International"买入"评级,目标价从23美元升至24美元;Ascendiant Capital:维持Synergy CHC Corp."买入"评级,目标价从5美元升至5.5美元
04-15 11:31
JP Morgan analyst Matthew Boss maintains LuxExperience (NYSE:LUXE) with a Neutral and lowers the price target from $10 to $9.
04-15 01:08
今日重点评级关注:杰富瑞:上调BioAge Labs评级至"买入",目标价从9美元升至62美元;RBC Capital:维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级,目标价从21美元升至22美元
02-19 16:21
绩优股霸屏!IPG光电涨超40%,Q4营收同比增加17%;康耐视科技涨近39%,Q4业绩超出市场预期;华仕伯涨近54%,有望获Transocean以58亿美元收购>>
02-14 10:36